Biogen makes up to $1B deal for secretive anti-inflammatory biotech
百健拟斥资最高10亿美元收购神秘抗炎生物技术公司

Biogen will pay as much as $1 billion — “predominantly” in milestone payments — to acquire a San Diego biotech that has disclosed little about its pipeline.
百健将斥资最高达10亿美元收购一家位于圣地亚哥的生物技术公司，其中大部分为里程碑付款；该公司对其在研产品披露甚少。